Efavirenz (Sustiva, Stocrin)

The Latest

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

By Barbara Jungwirth and Myles Helfand

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

By Barbara Jungwirth and Myles Helfand

Neurological Conditions More Likely Among Children Exposed to Efavirenz in Utero

Efavirenz (Sustiva, Stocrin) use was associated with a 60% increased risk of neurological conditions in children, according to data presented at IDWeek 2018 in San Francisco.

By Sony Salzman

Efavirenz Side Effects and Other Drug-Drug Interactions Are Common in Ugandan Cohort

Drug-drug interactions and side effects, associated with currently-used first-line antiretroviral therapy, are under-reported and managed in Uganda.

By Polly Clayden for HIV i-Base

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

By Polly Clayden for HIV i-Base

This Week in HIV Research: This Is Your Brain on (HIV) Drugs

NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.

By Barbara Jungwirth and Myles Helfand

High Rates of Undocumented Efavirenz-Related Side Effects in Uganda

Although central nervous system side effects associated with efavirenz have led to newer drugs being recommended in in high income countries, WHO guidelines for low and middle income countries still recommend efavirenz for first-line therapy.

By Simon Collins for HIV i-Base

How a Gene Test Can Solve Side Effects Linked to Antiretroviral Drugs in Africa

Researchers set out to find a way for HIV-positive people to continue using efavirenz (Sustiva, Stocrin) at lower doses in an effort to reduce severe side effects.

By Collen Masimirembwa for The Conversation

FDA Approved Changes to the Sustiva Label

FDA recently approved changes to the Sustiva (efavirenz, Stocrin) product labeling to include a new Warnings and Precautions regarding QTc prolongation.

By U.S. Food and Drug Administration